CG Oncology’s Loss Widens To $56.9 Million Ahead Of November Bladder-Cancer Trial Results
Research costs rose as the company prepares trial readouts and an FDA application, with cash expected to fund operations through 2029.
CG Oncology, which develops experimental bladder-cancer treatments, reported a third-quarter loss of $56.9 million Friday, compared with $43.8 million a year earlier. The results arrive ahead of anticipated November findings from a late-stage trial of cretostimogene, its investigational treatment.
Trial Spending Drives The Loss
Higher clinical-trial costs and a larger staff pushed research spending to $39.2 million, versus $27.9 million in the third quarter of 2025, the company said in its earnings release. The unaudited quarterly loss amounted to $0.64 per share, compared with $0.57 a year earlier.
Administrative expenses moved down to $23.0 million from $23.3 million. Savings on professional and consulting fees partly offset higher personnel expenses and other costs. Revenue totaled $1,604,000, versus $1,666,000 a year earlier.
For the first nine months of 2026, CG Oncology lost $196,149,000, compared with $119,686,000 in the same period of 2025.
Cash, cash equivalents and marketable securities stood at $984.5 million on September 30, down from $1.0 billion on June 30. Management expects those resources to fund operations through 2029.
Cretostimogene Approaches Its Next Readouts
The November readout comes from a late-stage study testing cretostimogene on its own as an additional treatment for intermediate-risk and high-grade Ta bladder cancer that has not invaded the muscle wall. December is expected to bring results tracking patients for 12 months from additional trial groups, including patients whose cancer has not responded to BCG treatment.
Cretostimogene is delivered directly into the bladder and is designed to attack cancer cells while activating an immune response against tumors. CG Oncology studies it both alone and alongside other cancer medicines in mid-stage and late-stage trials, and relies on third parties for manufacturing. As of January 30, 2026, more than 740 patients had received it across clinical trials.
The candidate has FDA Fast Track and Breakthrough Therapy designations for bladder cancer unresponsive to BCG. Its safety and effectiveness have not been established by the FDA or another health authority.
Arthur Kuan, CG Oncology’s chairman, president and CEO, said: “We remain confident in cretostimogene’s potential to become a backbone therapy for patients and to create long-term value for shareholders.”
Commercial Hiring Before The Application
CG Oncology appointed Isabel Kalofonos as chief commercial officer in October. The company cited her more than 20 years of experience, including launches of PALSONIFY and ELAHERE.
Management anticipates completing its FDA approval application in the fourth quarter of 2026. The initial indication would cover BCG-unresponsive bladder cancer with carcinoma in situ, with or without papillary disease.
The next expected milestone is November’s late-stage trial readout, followed by the additional 12-month results anticipated in December.
Sources
- 8-K Filing — CG Oncology, Inc. (CGON) — SEC EDGAR
- Exhibit cgon-20261106x8kexx991.htm — CG Oncology, Inc. 8-K exhibit — SEC EDGAR
- CG Oncology Reports Third Quarter 2026 Financial Results — globenewswire.com